Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

V212

Phase 3Biologic

V212 is one of 67 biologic programs targeting Autoimmune Disease. It is currently in Phase 3.

2

Indications

7

Total Trials

0

Active Trials

66

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autoimmune DiseaseActive, not recruiting

Herpes ZosterActive, not recruiting

Autoimmune DiseasePhase 2

Active, not recruiting

Herpes ZosterPhase 3

Active, not recruiting

Competition

Competitive Landscape

150 competitors in Autoimmune Disease

#DrugCompanyPhaseTrials

Myfortic

Remicade

OOrganon and Co

Atgam

Blincyto

Cytosar

Soliris

Rayos

RRoxane Laboratories

Bicnu

MMelissa K Accordino

Alkeran

Vepesid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Varicella Zoster2 trials

A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)

Withdrawn· Merck & Co. logo

Merck & Co.·Phase 3·NCT02180295

A Study to Evaluate Immunity to Varicella Zoster Virus After Immunization With V212 Vaccine or Zostavax (V212-003)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00886613·120 enrolled

Herpes Zoster2 trials

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Adult Participants With Solid Tumor or Hematologic Malignancy (V212-011)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01254630·5,305 enrolled

A Study to Evaluate the Safety and Efficacy of Inactivated Varicella-zoster Vaccine (VZV) as a Preventative Treatment for Herpes Zoster (HZ) and HZ-related Complications in Participants Undergoing Hematopoietic Cell Transplants (HCTs) (V212-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01229267·1,257 enrolled

Hematologic Malignancies1 trial

A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella-Zoster Virus (VZV) Vaccine in Adults With Hematologic Malignancies (HM) Receiving Treatment With Anti-Cluster of Differentiation (CD) 20 Monoclonal Antibodies (V212-013)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT01460719·80 enrolled

Autoimmune Disease1 trial

A Study to Evaluate the Safety and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Adults With Autoimmune Disease (V212-009)

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01527383·354 enrolled

Varicella-zoster Virus1 trial

A Study of an Investigational V212/Heat-Treated Varicella-Zoster Virus (VZV) Vaccine in Immunocompromised Adults (V212-002)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT00535236·341 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for V212. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — V212 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for V212. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Related News